

ImmusanT – working to help sufferers of coeliac disease

ImmusanT’s proprietary discovery platform has mapped the parts of nutritional gluten proteins that cause undesired immune activation in patients with coeliac disease according to their genetic background.



Leslie Williams, BS, RN, MBA, Director, Founder, CEO and President



ImmusanT is focused on restoring tolerance to gluten in coeliac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life.

Nexvax2® is a combination of three proprietary peptides designed to elicit an immune response in patients with celiac disease (CeD) who carry the immune recognition gene, HLA-DQ2.5, which accounts for the condition in 80% to 90% of patients. Nexvax2® is delivered intradermally as a therapeutic vaccine to reprogram the T-cells that respond to gluten antigens in CeD patients and prevent them from triggering a pro-inflammatory response.

ImmusanT has recently completed two Phase 1b safety, tolerability, and pharmacodynamics clinical trials in which Nexvax2® was found to engage antigenspecific target cells, and a distinct immunological signature was discovered. After repeated dosing, patients who received Nexvax2® were able to complete gluten challenge in contrast to placebo. The Phase 2 trial is expected to begin the end of the year.



Nexvax2® is the only disease-modifying therapeutic approach for coeliac disease in clinical development today that has the potential to enable patients to return to a normal diet, good health, and improved quality of life.

About ImmusanT

ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT has developed a therapy and personalised diagnostics for coeliac disease and is expanding to other autoimmune diseases including Type 1 diabetes.

To find out more



Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information may be found at www.ImmusanT.com or follow ImmusanT on Twitter.



Leslie Williams

Product	Discovery/IP	Preclinical	Phase 1	Phase 2
Nexvax2® Therapy	HLA DQ2.5 variant of coeliac disease			
Nexvax2® Companion & Diagnostic	Select patient for Nexvax® therapy & potentially replace endoscopic biopsy by blood test			
Immune Monitoring	Improve/replace blood tests for coeliac disease			
Next Generation Nexvax2® Therapy	Discover peptides for other variants of coeliac disease			
Type 1 Diabetes	Diagnostics and therapy for T1D			
Prevent Disease	Potentially prevent coeliac disease with Nexvax2® in susceptible patients			